Promising results of Providence-sponsored trial published in npj Breast Cancer

The final outcomes from a Providence Cancer Institute-sponsored phase Ib trial were published in npj Breast Cancer on June 21. The trial evaluated pembrolizumab, an immunotherapy, with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic triple-negative breast cancer. Both regimens achieved predetermined safety and efficacy outcomes. The study, “A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer,” was led by David B. Page, M.D., Providence Cancer Institute. npj Breast Cancer is an open access, multidisciplinary research journal dedicated to publishing leading-edge breast cancer research and treatment.  

Read about the trial.  

Related news

Providence researchers contribute to more than 20 studies presented at ASCO Annual Meeting

Breast cancer survivor, artist gives back to Providence

Providence Willamette Falls celebrates opening of new cancer center

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.
In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.
Providence Cancer Institute registered dietitian to present a free virtual education talk on nutrition in March.
New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy